Reduction in duodenal endocrine cells in irritable bowel syndrome is associated with stem cell abnormalities

Figure 1 Densities of musashi 1 and neurogenin 3 cells in controls and irritable bowel syndrome-total, irritable bowel syndrome-C, irritable bowel syndrome-D and irritable bowel syndrome-M patients. ^aP < 0.05, ^bP < 0.001 vs the control group.

Figure 2 Musashi-1-immunoreactive cells (arrows) in representative subjects from the (A) control, (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.

Figure 4 Densities of secretin, cholecystokinin, gastric inhibitory peptide, somatostatin and serotonin cells in controls and irritable bowel syndrome-total, irritable bowel syndrome-D, irritable bowel syndrome-M and irritable bowel syndrome-C patients. ^aP < 0.05, ^bP < 0.001 vs the control group.

Figure 5 Secretin cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.

Figure 6 Cholecystokinin-immunoreactive cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.

Figure 7 Gastric inhibitory peptide cells (arrows) in (A) a control subject (B) irritable bowel syndrome-D, (C) irritable bowel syndrome-M and (D) irritable bowel syndrome-C patients.